Devices and techniques for bariatric and metabolic endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review

Abstract

Endoscopic bariatric and metabolic therapies (EBMTs) are increasingly recognized as valuable tools for managing obesity and related metabolic disorders. As the prevalence of obesity continues to rise globally, there is a growing demand for effective, safe, and less invasive treatment options. This review provides a comprehensive summary of the available EBMTs, including both stomach-targeted and small-bowel-targeted devices. The review details the various devices, outlines the techniques for their proper use, and discusses their indications. It also presents data on their efficacy and safety, and the management of adverse events and weight regain, as well as anticipated future developments. The paper emphasizes the necessity for additional high quality randomized controlled trials and long-term outcome data to better define the role of these therapies within obesity treatment protocols. Overall, this review serves as an authoritative resource for endoscopists, bariatric specialists, and the wider healthcare community involved in obesity care, promoting best practices and guiding the appropriate implementation of EBMTs in clinical settings.

^‡ Joint first authors

Publication History

Article published online:
08 July 2025

• References

• 1 Bray GA, Kim KK, Wilding JPH. et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017; 18: 715-723
• 2 Chakraborti CK. New-found link between microbiota and obesity. World J Gastrointest Pathophysiol 2015; 6: 110
• 3 The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. NEJM 2017; 377: 13-27
• 4 Lauby-Secretan B, Scoccianti C, Loomis D. et al. Body fatness and cancer — viewpoint of the IARC Working Group. NEJM 2016; 375: 794-798
• 5 Brock JM, Billeter A, Müller-Stich BP. et al. Obesity and the lung: what we know today. Respiration 2020; 99: 856-866
• 6 World Health Organization. Obesity and overweight. Accessed: 12 September 2023. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
• 7 Singh N, Stewart RAH, Benatar JR. Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ Open 2019; 9: e029966
• 8 Wadden TA, Sternberg JA, Letizia KA. et al. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989; 13 (Suppl. 02) 39-46
• 9 Wharton S, Serodio KJ, Kuk JL. et al. Interest, views and perceived barriers to bariatric surgery in patients with morbid obesity. Clin Obes 2016; 6: 154-160
• 10 Pan X, Tan B, Chin YH. et al. Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity 2024; 32: 840-856
• 11 Grunvald E, Shah R, Hernaez R. et al. AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022; 163: 1198-1225
• 12 Jirapinyo P, Hadefi A, Thompson CC. et al. American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Gastrointest Endosc 2024; 99: 867-885.e64
• 13 Salminen P, Kow L, Aminian A. et al. IFSO consensus on definitions and clinical practice guidelines for obesity management—an international Delphi study. Obes Surg 2024; 34: 30-42
• 14 Abu Dayyeh BK, Bazerbachi F, Vargas EJ. et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet 2022; 400: 441-451
• 15 Kermansaravi M, Chiappetta S, Parmar C. et al. Current recommendations for procedure selection in class I and II obesity developed by an expert modified Delphi consensus. Sci Rep 2024; 14: 3445
• 16 Caiazzo R, Branche J, Raverdy V. et al. Efficacy and safety of the duodeno-jejunal bypass liner in patients with metabolic syndrome: a multicenter randomized controlled trial (ENDOMETAB). Ann Surg 2020; 272: 696-702
• 17 Angelini G, Salinari S, Castagneto-Gissey L. et al. Small intestinal metabolism is central to whole-body insulin resistance. Gut 2021; 70: 1098-1109
• 18 Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: Results of a prospective study. Obesity 2016; 24: 1849-1853
• 19 Neto MG, Silva LB, Grecco E. et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis 2018; 14: 151-159
• 20 Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg 2008; 18: 1611-1617
• 21 Abu Dayyeh BK, Acosta A, Camilleri M. et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol 2017; 15: 37-43.e1
• 22 Huberty V, Ibrahim M, Hiernaux M. et al. Safety and feasibility of an endoluminal-suturing device for endoscopic gastric reduction (with video). Gastrointest Endosc 2017; 85: 833-837
• 23 Lopez-Nava G, Asokkumar R, Turró Arau R. et al. Modified primary obesity surgery endoluminal (POSE-2) procedure for the treatment of obesity. VideoGIE 2020; 5: 91-93
• 24 Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc 2013; 78: 530-535
• 25 Reitano E, Riva P, Keller D. et al. Deep sedation versus orotracheal intubation for endoscopic sleeve gastroplasty (ESG): preliminary experience. Surg Endosc 2023; 37: 6513-6518
• 26 Neto MG, Silva LB, De Quadros LG. et al. Brazilian consensus on endoscopic sleeve gastroplasty. Obes Surg 2021; 31: 70-78
• 27 Bove V, Gallo C, Pontecorvi V. et al. Common and uncommon problems during endoscopic suturing with Apollo Overstitch: tips and tricks for troubleshooting. Tech Innov Gastrointest Endosc 2021; 23: 220-225
• 28 Abu Dayyeh BK. Interlocking endoscopic sleeve gastroplasty with next-generation suturing device. VideoGIE 2024;
• 29 Joseph S, McGowan CE, Jirapinyo P. et al. Endoscopic sleeve gastroplasty: the identification of the key procedural steps through a modified Delphi method. J Gastrointest Surg 2024; 28: 1132-1136
• 30 Espinet-Coll E, Nebreda-Durán J, Galvao-Neto M. et al. Suture pattern does not influence outcomes of endoscopic sleeve gastroplasty in obese patients. Endosc Int Open 2020; 8: E1349-E1358
• 31 Matteo MV, Pontecorvi V, Bove V. et al. Prospective, single-arm multicenter, international, observational postmarket study to assess the safety and efficacy of a triangulation platform for treating patients requiring endoscopic gastroplasty. Gastrointest Endosc 2025; 101: 106-116.e1
• 32 Gkolfakis P, van Ouytsel P, Mourabit Y. et al. Weight loss after endoscopic sleeve gastroplasty is independent of suture pattern: results from a randomized controlled trial. Endosc Int Open 2022; 10: E1245-E1253
• 33 Sullivan S, Swain JM, Woodman G. et al. Randomized sham‐controlled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. Obesity 2017; 25: 294-301
• 34 Lopez Nava G, Arau RT, Asokkumar R. et al. Prospective multicenter study of the Primary Obesity Surgery Endoluminal (POSE 2.0) procedure for treatment of obesity.. Clin Gastroenterol Hepatol 2023; 21: 81-89.e4
• 35 Jirapinyo P, Thompson CC. Comparison of distal primary obesity surgery endolumenal techniques for the treatment of obesity (with videos). Gastrointest Endosc 2022; 96: 479-486
• 36 Bove V, Matteo MV, Pontecorvi V. et al. Robotic endoscopic sleeve gastroplasty. Gut 2023; 72: 27-29
• 37 Marinos G, Eliades C, Raman Muthusamy V. et al. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Relat Dis 2014; 10: 929-934
• 38 Greenway FL, Aronne LJ, Raben A. et al. A randomized, double‐blind, placebo‐controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity 2019; 27: 205-216
• 39 Thompson CC, Abu Dayyeh BK, Kushner R. et al. Percutaneous gastrostomy device for the treatment of class II and class III obesity: results of a randomized controlled trial. Am J Gastroenterol 2017; 112: 447-457
• 40 FDA News Release. FDA approves AspireAssist obesity device; 14 June 2016. Accessed: 25 March 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-aspireassist-obesity-device
• 41 Aspire. Aspire Bariatrics Company Update; 12 February 2022. Accessed: 12 July 2024 https://www.aspirebariatrics.com
• 42 Rodriguez L, Reyes E, Fagalde P. et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther 2009; 11: 725-732
• 43 Ren M, Zhou X, Yu M. et al. Prospective study of a new endoscopic duodenal–jejunal bypass sleeve in obese patients with nonalcoholic fatty liver disease (with video). Dig Endosc 2023; 35: 58-66
• 44 Sandler BJ, Biertho L, Anvari M. et al. Totally endoscopic implant to effect a gastric bypass: 12-month safety and efficacy outcomes. Surg Endosc 2018; 32: 4436-4442
• 45 Haidry RJ, van Baar AC, Galvao Neto MP. et al. Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting. Gastrointest Endosc 2019; 90: 673-681.e2
• 46 Rajagopalan H, Cherrington AD, Thompson CC. et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 2016; 39: 2254-2261
• 47 van Baar ACG, Haidry R, Rodriguez Grunert L. et al. Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitus. Endosc Int Open 2020; 8: E1683-E1689
• 48 Sartoretto A, O’Neal D, Holt B. et al. Duodenal mucosal regeneration induced by endoscopic pulsed electric field treatment improves glycemic control in patients with type II diabetes - interim results from a first-in-human study. Gastrointest Endosc 2023; 97: AB11-AB12
• 49 Machytka E, Bužga M, Zonca P. et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc 2017; 86: 904-912
• 50 Ryou M, Aihara H, Thompson CC. Minimally invasive entero-enteral dual-path bypass using self-assembling magnets. Surg Endosc 2016; 30: 4533-4538
• 51 Abu Dayyeh BK, Kumar N, Edmundowicz SA. et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82: 425-438.e5
• 52 Kumar N, Bazerbachi F, Rustagi T. et al. The influence of the Orbera intragastric balloon filling volumes on weight loss, tolerability, and adverse events: a systematic review and meta-analysis. Obes Surg 2017; 27: 2272-2278
• 53 Popov VB, Ou A, Schulman AR. et al. The impact of intragastric balloons on obesity-related co-morbidities: a systematic review and meta-analysis. Am J Gastroenterol 2017; 112: 429-439
• 54 Abu Dayyeh BK, Maselli DB, Rapaka B. et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet 2021; 398: 1965-1973
• 55 Sullivan S, Swain J, Woodman G. et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis 2018; 14: 1876-1889
• 56 Ponce J, Woodman G, Swain J. et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015; 11: 874-881
• 57 Vantanasiri K, Matar R, Beran A. et al. The efficacy and safety of a procedureless gastric balloon for weight loss: a systematic review and meta-analysis. Obes Surg 2020; 30: 3341-3346
• 58 Aoko O, Maharaj T, Boland F. et al. Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Aliment Pharmacol Ther 2024; 59: 8-22
• 59 Silva AF, Bestetti AM, Kum AST. et al. Effectiveness and safety of the Allurion swallowable intragastric balloon for short-term weight loss: a systematic review and meta-analysis. Obes Surg 2024; 34: 3735-3747
• 60 Chan DL, Cruz JR, Mui WL. et al. Outcomes with intra-gastric balloon therapy in BMI < 35 non-morbid obesity: 10-year follow-up study of an RCT. Obes Surg 2021; 31: 781-786
• 61 Kotzampassi K, Grosomanidis V, Papakostas P. et al. 500 Intragastric balloons: what happens 5 years thereafter?. Obes Surg 2012; 22: 896-903
• 62 Hedjoudje A, Abu Dayyeh BK, Cheskin LJ. et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020; 18: 1043-1053.e4
• 63 Nunes BCM, de Moura DTH, Kum AST. et al. Impact of endoscopic sleeve gastroplasty in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Obes Surg 2023; 33: 2917-2926
• 64 Huberty V, Boskoski I, Bove V. et al. Endoscopic sutured gastroplasty in addition to lifestyle modification: short-term efficacy in a controlled randomised trial. Gut 2021; 70: 1479-1485
• 65 AlKhatry M, Rapaka B, Maselli DB. et al. Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2. 0 procedure. Endoscopy 2023; 55: 1028-1034
• 66 Jense MTF, Hodde T, Palm-Meinders IH. et al. The POSE-2 procedure for people with obesity: a safe and effective treatment option. Obes Surg 2024; 34: 3686-3693
• 67 Boskoski I, Lopez-Nava G, Ravishankar A. et al. Automatic endoscopic gastroplasty for the treatment of obesity: results from a prospective multicenter study (with video). Gastrointest Endosc 2024;
• 68 Lopez-Nava G, Laster J, Negi A. et al. Endoscopic sleeve gastroplasty (ESG) for morbid obesity: how effective is it?. Surg Endosc 2022; 36: 352-360
• 69 Gala K, Brunaldi V, McGowan C. et al. Performance of endoscopic sleeve gastroplasty by obesity class in the United States clinical setting. Clin Transl Gastroenterol 2024; 15: e00647
• 70 Alqahtani A, Elahmedi M, Alqahtani YA. et al. Endoscopic sleeve gastroplasty in 109 consecutive children and adolescents with obesity: two-year outcomes of a new modality. Am J Gastroenterol 2019; 114: 1857-1862
• 71 Matteo MV, Bove V, Pontecorvi V. et al. Outcomes of endoscopic sleeve gastroplasty in the elder population. Obes Surg 2022; 32: 3390-3397
• 72 Sharaiha RZ, Hajifathalian K, Kumar R. et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol 2021; 19: 1051-1057.e2
• 73 Fehervari M, Fadel MG, Alghazawi LOK. et al. Medium-term weight loss and remission of comorbidities following endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Obes Surg 2023; 33: 3527-3538
• 74 Lopez-Nava G, Ravishankar A, Matteo MV. et al. S1642 Robotic endoscopic sleeve gastroplasty for the treatment of obesity: an interim analysis of a multicenter pilot study. Am J Gastroenterol 2023; 118: S1230-S1230
• 75 Thompson CC, Abu Dayyeh BK, Kushnir V. et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis 2019; 15: 1348-1354
• 76 Jirapinyo P, de Moura DTH, Horton LC. et al. Effect of aspiration therapy on obesity-related comorbidities: systematic review and meta-analysis. Clin Endosc 2020; 53: 686-697
• 77 U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED): TransPyloric Shuttle. Accessed 25 March 2025 https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180024B.pdf
• 78 Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care 2018; 41: 1106-1115
• 79 Roehlen N, Laubner K, Nicolaus L. et al. Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus. Nutrition 2022; 103–104: 111806
• 80 Oh JH, Kang D, Kang W. et al. Proton pump inhibitor use increases pyogenic liver abscess risk: a nationwide cohort study. J Neurogastroenterol Motil 2021; 27: 555-564
• 81 Sandler BJ, Rumbaut R, Swain CP. et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 2015; 29: 3298-3303
• 82 van Baar ACG, Holleman F, Crenier L. et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut 2020; 69: 295-303
• 83 Mingrone G, van Baar AC, Devière J. et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut 2022; 71: 254-264
• 84 de Oliveira GHP, de Moura DTH, Funari MP. et al. Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis. Obes Surg 2021; 31: 1304-1312
• 85 van Baar ACG, Meiring S, Smeele P. et al. Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study. Gastrointest Endosc 2021; 94: 111-120.e3
• 86 Hadefi A, Verset L, Pezzullo M. et al. Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. Endosc Int Open 2021; 9: E1792-E1800
• 87 Busch CBE, Meiring S, van Baar ACG. et al. Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human study. Gastrointest Endosc 2024; 100: 896-904
• 88 Ribeiro IB, Kotinda APST, Sánchez-Luna SA. et al. Adverse events and complications with intragastric balloons: a narrative review (with video). Obes Surg 2021; 31: 2743-2752
• 89 Kozłowska-Petriczko K, Pawlak KM, Wojciechowska K. et al. The efficacy comparison of endoscopic bariatric therapies: 6-month versus 12-month intragastric balloon versus endoscopic sleeve gastroplasty. Obes Surg 2023; 33: 498-505
• 90 de Peppo F, Caccamo R, Adorisio O. et al. The Obalon swallowable intragastric balloon in pediatric and adolescent morbid obesity. Endosc Int Open 2017; 5: E59-E63
• 91 Jamal MH, Almutairi R, Elabd R. et al. The safety and efficacy of procedureless gastric balloon: a study examining the effect of elipse intragastric balloon safety, short and medium term effects on weight loss with 1-year follow-up post-removal. Obes Surg 2019; 29: 1236-1241
• 92 Wiggins T, Sharma O, Sarfaraz Y. et al. Safety and efficacy of 12-month intra-gastric balloon—series of over 1100 patients. Obes Surg 2024; 34: 176-182
• 93 Sartoretto A, Sui Z, Hill C. et al. Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption: a large, international multicenter study. Obes Surg 2018; 28: 1812-1821
• 94 Lopez-Nava G, Sharaiha RZ, Vargas EJ. et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg 2017; 27: 2649-2655
• 95 Li P, Ma B, Gong S. et al. Efficacy and safety of endoscopic sleeve gastroplasty for obesity patients: a meta-analysis. Surg Endosc 2020; 34: 1253-1260
• 96 Lopez-Nava G, Asokkumar R, Rull A. et al. Safety and feasibility of a novel endoscopic suturing device (EndoZip TM) for treatment of obesity: first-in-human study. Obes Surg 2020; 30: 1696-1703
• 97 Betzel B, Drenth JPH, Siersema PD. Adverse events of the duodenal-jejunal bypass liner: a systematic review. Obes Surg 2018; 28: 3669-3677
• 98 Sandler BJ, Rumbaut R, Swain CP. et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 2011; 25: 3028-3033
• 99 Brolin RE. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2007; 246: 163-164
• 100 Magro DO, Geloneze B, Delfini R. et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg 2008; 18: 648-651
• 101 Scarpellini E, Arts J, Karamanolis G. et al. International consensus on the diagnosis and management of dumping syndrome. Nat Rev Endocrinol 2020; 16: 448-466
• 102 Matteo MV, Gallo C, Pontecorvi V. et al. Weight recidivism and dumping syndrome after Roux-En-Y gastric bypass: exploring the therapeutic role of transoral outlet reduction. J Pers Med 2022; 12: 1664
• 103 Athanasiadis DI, Martin A, Kapsampelis P. et al. Factors associated with weight regain post-bariatric surgery: a systematic review. Surg Endosc 2021; 35: 4069-4084
• 104 Abu Dayyeh BK, Lautz DB, Thompson CC. Gastrojejunal stoma diameter predicts weight regain after Roux-en-Y gastric bypass. Clin Gastroenterol Hepatol 2011; 9: 228-233
• 105 Coakley BA, Deveney CW, Spight DH. et al. Revisional bariatric surgery for failed restrictive procedures. Surg Obes Relat Dis 2008; 4: 581-586
• 106 Szvarca D, Jirapinyo P. Endoscopic management of weight regain after bariatric surgery. Gastrointest Endosc Clin N Am 2024; 34: 639-654
• 107 Pontecorvi V, Matteo MV, Bove V. et al. Long-term outcomes of transoral outlet reduction (TORe) for dumping syndrome and weight regain after Roux-en-Y gastric bypass. Obes Surg 2023; 33: 1032-1039
• 108 Brunaldi VO, Jirapinyo P, de Moura DTH. et al. Endoscopic treatment of weight regain following Roux-en-Y gastric bypass: a systematic review and meta-analysis. Obes Surg 2018; 28: 266-276
• 109 Dhindsa BS, Saghir SM, Naga Y. et al. Efficacy of transoral outlet reduction in Roux-en-Y gastric bypass patients to promote weight loss: a systematic review and meta-analysis. Endosc Int Open 2020; 8: E1332-E1340
• 110 Jirapinyo P, Thompson CC. Endoscopic gastric plication for the treatment of weight regain after Roux-en-Y gastric bypass (with video). Gastrointest Endosc 2022; 96: 51-56
• 111 Vargas EJ, Abu Dayyeh BK, Storm AC. et al. Endoscopic management of dumping syndrome after Roux-en-Y gastric bypass: a large international series and proposed management strategy. Gastrointest Endosc 2020; 92: 91-96
• 112 Jirapinyo P, de Moura DTH, Thompson CC. Endoscopic submucosal dissection with suturing for the treatment of weight regain after gastric bypass: outcomes and comparison with traditional transoral outlet reduction (with video). Gastrointest Endosc 2020; 91: 1282-1288
• 113 Di Lorenzo N, Camperchioli I, Scozzarro A. et al. Bariatric reduction system – BARS: device, technique and first clinical experience. Minim Invasive Ther Allied Technol 2021; 30: 187-194
• 114 Kalapala R, Inavolu P, Sai Kumar C. et al. Novel approach for weight reduction after Roux-en-Y gastric bypass with weight regain: a combination of Bariatric Anastomotic Reduction System with tubularization of residual gastric pouch. VideoGIE 2024; 9: 521-524
• 115 Alkhatry M, Al-Haddad M, Housen F. et al. Durability and weight outcomes of the bariatric anastomotic reduction system clips in patients with refractory weight regain after (RYGB) gastric bypass surgery: a 1-year follow-up study. Am J Gastroenterol 2024; 119: S1473-S1473
• 116 Maselli DB, Alqahtani AR, Abu Dayyeh BK. et al. Revisional endoscopic sleeve gastroplasty of laparoscopic sleeve gastrectomy: an international, multicenter study. Gastrointest Endosc 2021; 93: 122-130
• 117 Maselli DB, Donnangelo LL, Coan B. et al. How to establish an endoscopic bariatric practice. World J Gastrointest Endosc 2024; 16: 178-186
• 118 Saumoy M, Gandhi D, Buller S. et al. Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses. Gut 2023; 72: 2250-2259
• 119 Kelly J, Menon V, O’Neill F. et al. UK cost-effectiveness analysis of endoscopic sleeve gastroplasty versus lifestyle modification alone for adults with class II obesity. Int J Obes 2023; 47: 1161-1170
• 120 Gonzalez JM, Ouazzani S, Monino L. et al. First fully endoscopic metabolic procedure with NOTES gastrojejunostomy, controlled bypass length and duodenal exclusion: a 9-month porcine study. Sci Rep 2022; 12: 21
• 121 Angelini G, Galvao Neto M, Boskoski I. et al. ForePass endoscopic bypass device for obesity and insulin resistance—metabolic treatment in a swine model. Gut 2024; 73: 568-572
• 122 Shnell M, Scapa E, Matteo MV. et al. Animal experiments of a new through-the-scope full-thickness endoscopic suturing device. Gut 2024; 73: 1931-1933
• 123 Rodríguez de Santiago E, Dinis-Ribeiro M, Pohl H. et al. Reducing the environmental footprint of gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Position Statement. Endoscopy 2022; 54: 797-826